MENLO PARK, Calif. & CORONA, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ: DEPO) and Watson Pharmaceuticals, Inc. (NYSE: WPI) announced today that the companies have expanded their co-promotion agreement to grant Watson the right to promote Depomed’s ProQuin® XR in the obstetrics/gynecology (Ob/Gyn) specialty market area. ProQuin XR is a once-daily, extended-release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections. This agreement expands the relationship entered into in July 2007 for the promotion to both urology and long-term care specialty areas in the United States.
